β tubulin mutations are rare in human ovarian carcinoma

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 681-686

  Lamendola, Diana E ^a   Duan, Zhenfeng ^a   Penson, Richard T ^a   Oliva, Esther ^a   Seiden, Michael V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drug resistance; Paclitaxel; Pseudogenes

Indexed keywords

BETA TUBULIN; CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CYTOTOXICITY; DRUG BINDING; EXON; GENE MUTATION; HUMAN; HUMAN TISSUE; OVARY CARCINOMA; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; DNA, NEOPLASM; EXONS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RETROSPECTIVE STUDIES; TUBULIN;

EID: 0037231184     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ra S, Horwitz SB and Ringel I: Direct photoaffinity labeling of tubulin with taxol. J Natl Cancer Inst 84: 785-788, 1992.
2. Diaz JF and Andreu JM: Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 32: 2747-2755, 1993.
3. Linse K and Mandelkow EM: The GTP-binding peptide of beta-tubulin. Localization by direct photoaffinity labeling and comparison with nucleotide-binding proteins. J Biol Chem 263: 15205-15210, 1988.
4. Shivanna BD, Mejillano MR, Williams TD and Himes RH: Exchangeable GTP binding site of beta-tubulin. Identification of cysteine 12 as the major site of cross-linking by direct photoaffinity labeling. J Biol Chem 268: 127-132, 1993.
5. Nogales E, Wolf SG and Downing KH: Structure of the alpha beta tubulin dimer by electron crystallography. Nature 391: 199-203, 1998.
6. Snyder JP, Nettles JH, Cornett B, Downing KH and Nogales E: The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci USA 98: 5312-5316, 2001.
7. Dumontet C, Duran GE, Stege, KA, Beketic-Oreskovic L and Sikic BI: Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56: 1091-1097, 1996.
8. Germann UA: P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927-944, 1996.
9. Parekh H, Wiesen K and Simpkins H: Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol 53: 461-470, 1997.
10. Strobel T, Kraeft SK, Chen LB and Cannistra SA: BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res 58: 4776-4781, 1998.
11. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G and Blialla K: High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8: 1960-1969, 1994.
12. Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070, 1999.
13. Haber M, Burkhart CA, Regl DL, Madafigho J, Norris MD and Horwitz SB: Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 270: 31269-31275, 1995.
14. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW and Hudes GR: Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77: 562-566, 1998.
15. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T and Poruchynsky MS: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118-17125, 1997.
16. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY and Martin C: Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17: 1786-1793, 1999.
17. Orita M, Suzuki Y, Sekiya T and Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879, 1989.
18. Orita M, Iwahana H, Kanazawa H, Hayashi K and Sekiya T: Detection of polymorphisms, of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86: 2766-2770, 1989.
19. Vidal-Puig A and Moller DE: Comparative sensitivity of alternative single-strand conformation polymorphism (SSCP) methods. Biotechniques 17: 490-492, 494, 496, 1994.
20. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC and Fojo T: A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 97: 2904-2909, 2000.
21. Lee MG, Lewis SA, Wilde CD and Cowan NJ: Evolutionary history of a multigene family: an expressed human beta-tubulin gene and three processed pseudogenes. Cell 33: 477-487, 1983.
22. van Geel M, van Deutekom JC, van Staalduinen A, Lemmers RJ, Dickson MC, Hofker MH, Padberg GW, Hewitt JE, de Jong PJ and Frants RR: Identification of a novel beta-tubulin subfamily with one member (TUBB4Q) located near the telomere of chromosome region 4q35. Cytogenet Cell Genet 88: 316-321, 2000.
23. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV and Fojo T: Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 19: 3078-3085, 2000.
24. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71: 543-546, 1992.
25. Havre PA, Yuan J, Hedrick L, Cho KR and Glazer PM: p53 inactivation by HPV 16 E6 results in increased mutagenesis in human cells. Cancer Res 55: 4420-4424, 1995.
26. Liu PK, Kraus E, Wu TA, Strong LC and Tainsky MA: Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations. Oncogene 12: 2267-2278, 1996.
27. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF and Minna JD: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989.
28. Okamoto A, Santeshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M and Yokota J: Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 51: 5171-5176, 1991.
29. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC Jr and Berchuck A: Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85: 1513-1519, 1993.
30. Henderson BE, Ross RK and Pike MC: Toward the primary prevention of cancer. Science 254: 1131-1138, 1991.
31. Ames BN, Gold LS and Willett WC: The causes and prevention of cancer. Proc Natl Acad Sci USA 92: 5258-5265, 1995.